Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials
Tirzepatide may be an effective treatment for older adults without obesity, and in this post hoc analysis, it was associated with clinically relevant HbA1c reduction and dose-proportional weight loss without increasing hypoglycemic risk.
Authors
- Jim S Paik (ORCID: https://orcid.org/0009-0000-7134-3519)
- Anita Y. M. Kwan
- John P.H. Wilding (ORCID: https://orcid.org/0000-0003-2839-8404)
- Jennifer Peleshok
- Neda Rasouli (ORCID: https://orcid.org/0000-0003-1269-3580)
- Palash Sharma (ORCID: https://orcid.org/0000-0003-3016-7541)
Institutions
- University of Liverpool (GB)
- Eli Lilly (United States) (US)
- VA Eastern Colorado Health Care System (US)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1007/s13300-025-01711-0
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- Eli Lilly and Company